Re: Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial.
D000279:Administration, Cutaneous; D000284:Administration, Oral; D000368:Aged; D000818:Animals; D016588:Anticarcinogenic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000975:Antioxidants / Q000008:administration & dosage; D004249:DNA Damage / Q000187:drug effects; D004359:Drug Therapy, Combination; D005260:Female; D019337:Hematologic Neoplasms / Q000139:chemically induced; D006801:Humans; D008113:Liver Neoplasms / Q000139:chemically induced; D008175:Lung Neoplasms / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000139:chemically induced*; D011471:Prostatic Neoplasms / Q000517:prevention & control*; D016032:Randomized Controlled Trials as Topic; D051381:Rats; D011919:Rats, Inbred Strains; D018036:Selenium Compounds / Q000008:administration & dosage* / Q000009:adverse effects; D012878:Skin Neoplasms / Q000517:prevention & control*; D013736:Testicular Neoplasms / Q000139:chemically induced; D014810:Vitamin E / Q000008:administration & dosage
D016588:Anticarcinogenic Agents; D000975:Antioxidants; D018036:Selenium Compounds; D014810:Vitamin E; C025698:selenium disulfide